CD33 and acute myeloid leukemia: The novel idea behind this approach is that such constructs will specifically target AML blasts and leukemia-initiating cells as they carry both CD33 and FLT3 markers; however, normal hematopoietic stem cells will be unharmed as they carry the endomucin (EMCN) marker.